Its probably best to mitigate duplicate questions to pop a list up. I am happy to email these to IR once we have a collated list of questions if people prefer.
My questions are:
- Commentary provided in recent webinars indicated robust orders for the products with an indication Febridx was seeing good uptake. This appears not to be the case as the product revenues for this quarter were again heavily reliant on Viradx, a product which we have been advised will cease. In the short term (3-6 months) are we expected to see a substantial increase in the revenues for Febridx as this is the long term product?
- Has Lumos engaged in marketing of the product in Australia and has there been any solid engagement from the health sector or Government to take up the product as a regular tool in their kit bags?
- Can Lumos provide a comparative breakdown on the revenues for each product per region to provide better clarity on the uptake of the individual products? I cant fathom how the products which have been in market for some time (globally) have not attracted an increase in sales comparatively to previous years. Lumos generated $320,000 in product sales in 2023 which was attributed to the international market (excluding AUS/NZ and the recent Henry Schein expansion to Belgium etc). $1.2Million in 2024 which includes the newly established US market. This is a substantial drop from Covid sales of circa $2.2Million. Even with an increase in the coming quarter (similar to the current quarter for 2023), the projection appears bleak for any increase in product sales compared the the previous corresponding period and that is with an increase to 30+ distribution partners.
- Lumos has always indicated it is primarily a services company first and a product company second. Removing the Hologic partnership (which is inflating revenue numbers per quarter through accounting methods) and no guarantee of ongoing revenues from this partnership, can Lumos please clarify in more detail its existing partnerships with other companies including Burnett Institute, MicroPak, Binx, Liaison as well as further information on the food safety testing, and animal health products? It is still quite unclear what these partnerships mean for the long term of the company. Are partnerships with Liaison etc still active?
- The company has always said it is unhappy with the current state of the share price and where its trajectory has been. What is the company doing to provide a robust platform for growth in the share price and a reasonable return to shareholders? At time of providing these questions, the share price has dropped 97% from initial IPO price. It has dropped a relative 73% from the FDA approval price. It has now dropped a relative 10.5% from the recent capital raising price.
LDX Price at posting:
3.5¢ Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)